Clinical trial
Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With…
NCT00061477 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00061477 |
|---|---|
| Title | Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma |
| Official title | ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mesothelioma |
| Intervention type | Drug |
| Interventions | Pemetrexed, Gemcitabine |
| Enrollment | 48 |
| Start date | Dec 1, 2002 |
| Completion | Sep 1, 2006 |
| First posted | May 29, 2003 |
| Last update posted | Jan 26, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: